Background and Objective: HBeAg-positive chronic hepatitis B patients have high serum HBV DNA level showing high viral replication. Goal of treatment of hepatitis B is to prevent cirrhosis, hepatic failure and hepatocellular carcinoma by serum alanine transaminase (ALT) normalization, decrease in serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) and loss in hepatitis B e antigen (HBeAg). Interferons (IFNs) have antiviral, anti-proliferative, and immunomodulatory effects. IFN-α is effective in suppressing HBV replication and in inducing remission of liver disease. Materials and Methods: In this prospective, single treatment arm study, HBeAg-positive chronic hepatitis patients without decompensated liver disease were enrolled to receive indigenous recombinant IFN-α 2b in the dose of 5 MU daily for 6 days a week subcutaneously for 16 weeks. Quantitative HBV-DNA, HBeAg, and hepatitis B surface antigen (HBsAg) were assessed at baseline and at the end of treatment. ALT level assessment was done at baseline and during therapy at week 1, week 2, week 8, week 12, and week 16. Results: Out of 37 patients enrolled in the study, 8 patients (21.62%) did not complete study due to lost to follow-up (3 patients), discontinuation due to adverse event (3 patients), and consent withdrawal (2 patients). Among 29 patients who completed the study, 10 patients (34.48%) had clearance of HBeAg and 1 patient (3.44%) had lost HBsAg after 16 weeks of therapy. Mean ALT level started decreasing after 4 weeks of therapy but did not come to normal range till 16 weeks of therapy. At least 2 log decreases in HBV DNA was observed in 9 (31.03%) patients and at least 1 log decrease in 18 (62.06%) patients. Overall decline in HBV DNA level was observed in 62% patients after 16 weeks of therapy. Conclusion: IFN-α treatment does result in HBeAg and HBsAg loss and decreases HBV-DNA levels in chronic hepatitis B patients. Most of adverse events were mild to moderate in intensity. So, interferon-α therapy was well tolerated, safe, and efficacious to treat HBeAg-positive chronic hepatitis B patients without decompensated liver disease.
INTRODUCTION
Hepatitis B is a potentially life-threatening viral infection of the liver. Hepatitis B virus (HBV) is a deoxyribonucleic acid (DNA) virus with compact genome that primarily interferes with the functions of liver by replicating in hepatocytes. Worldwide, an estimated two billion people have been infected with the HBV, and more than 350 million have chronic infection. [1] It is a major health problem in India with average estimated carrier rate of 4.0%, with a total pool of approximately 36 million carriers. [2] Professional blood donors have HBsAg positivity rate of 14%. HBV is reported to be responsible for 70% of cases of chronic hepatitis and 80% of cases of cirrhosis of the liver. [2] HBV transmission results from exposure to infectious blood or body fluids. Possible modes of transmission are unprotected sex, blood transfusion, contaminated needles and syringes, and vertical transmission during childbirth. [3] The risk of vertical transmission is high if mother is hepatitis B e antigen (HBeAg)-positive. HBV can also survive outside the body for prolonged period. [4, 5] After infection, the first virologic marker detectable in serum is hepatitis B surface antigen (HBsAg) that precedes elevation of serum aminotransferase activity and clinical symptoms. The most essential factor in patients with chronic hepatitis B is degree of HBV replication. Chronic HBV infection with ongoing viral replication is indicated by the presence of HBeAg and high HBV DNA level in serum. Many antiviral and immunomodulatory drugs have been tried, interferon alpha IFN-α in particular have been studied extensively. Recombinant IFN-α 2b increases the rate of elimination of HBeAg from low rate of spontaneous clearance of 5-10% without treatment to between 30-50% with treatment. [6] Seroconversion from HBeAg to anti-HBeAg antibodies leads to disappearance of serum HBV DNA level. [7] [8] [9] 
MATERIALS AND METHODS
The study was prospective, open-label, single arm with an objective of to evaluate the safety and efficacy IFN-α 5MU daily for 6 days a week for 16 weeks subcutaneously in patients with chronic hepatitis B. The study was conducted from Patients satisfying the eligibility criteria were enrolled in the study. Patients at each site were enrolled only after receiving approval from the respective institutional ethics committee and from regulatory authorities. All patients gave written informed consent prior to enrollment in the study.
Each of the patients enrolled on the study received recombinant IFN-α 2b (ReliFeron TM ) in the dose of 5MU daily for 6 days a week subcutaneously for 16 weeks. Quantitative HBV-DNA, HBeAg, and HBsAg were assessed at baseline and at the end of treatment. Alanine transaminase (ALT) level assessment was done at baseline and during therapy at week 1, week 2, week 8, week 12, and week 16.
HBV DNA purification, polymerase chain reaction (PCR) amplification, and quantification 4-5 ml blood samples collected in EDTA vacutainers or in plain vacutainers for serum. DNA was extracted from plasma of the patient samples using Qiagen RNA extraction kit.
Quantitative HBV PCR assay in pre-X region of the virus, serial dilutions of samples for viral load estimation was done. The lower limit of detection of the virus was 250 IU/ml (1250 copies/ml), and the assay sensitivity was 97-99%.
PCR was used to amplify pre-X region of HBV virus in the sample, using four serial dilutions (including original) of the DNA. HBV-specific primers were used to amplify the sample DNAs and subject to agarose electrophoresis. The intensity of the PCR products in comparison to defined quantitative ladder was used to quantitate HBV DNA in the samples. Additionally, quantitated positive control, negative control, and reaction control were used to validate the assay.
Statistical analysis
Data processing, tabulation of descriptive statistics, calculation of inferential statistics were performed primarily using SAS Version 9.1 for Windows. The HBV DNA and other laboratory values were expressed as mean, median, and percentage. Log change in HBV DNA value was tabulated in terms of counts and proportions along with 95% confidence interval.
Patient disposition and demography
Subjects were enrolled in single tertiary center. Thirty-seven subjects enrolled at baseline were qualified for this analysis. There were 31 (83.78%) male subjects and 6 (16.21%) female subjects in the study. The mean age of patients was 30 years, while mean body mass index was 21.04 kg/m 2 at baseline [ Table 1 ].
At baseline, all patients were HBsAg and HBeAg-positive. Before start of therapy, serum HBV DNA was measured in all patients. In 3 (8.10%) patients, HBV DNA was not detected at baseline. Fourteen (37.83%) patients had >10 7 copies/ml of HBV DNA, and 19 (51.35%) patients had HBV DNA level between 10 4 and 10 7 copies per ml. Mean ALT level in 37 patients at baseline was 112.48 U/L ranging from 44.00 to 424.00 U/L [ Table 2 ].
RESULTS

Efficacy results
Out of 37 HBeAg and HBsAg-positive patients enrolled in the study, 8 (21.62%) patients did not complete study due to lost to follow-up (3), discontinued due to adverse event (3), and consent withdrawal (2) . Among 29 patients treated with IFN-α, 10 (34.48%) patients had clearance of HBeAg and 1 (3.44%) patient had lost HBsAg after 16 weeks of therapy [ Table 3 ]. IFN-α-induced HBeAg clearance has been reported to be durable in 80% to 90% of patients after long-term follow-up of 4 to 8 years. [10] [11] [12] [13] [14] [15] [16] [17] However, HBV DNA remains detectable in serum in most of the patients. Studies comparing the outcome of responders versus non-responders found that patient who cleared HBeAg had better overall survival and survival free of hepatic de-compensation. [10, 11, 13, 18] Serum HBV DNA was assessed at baseline and end of therapy (16 weeks). After therapy, only 6 (20.68%) patients had HBV DNA level >10 7 copies/ml as compared to 14 (37.83%) patients at baseline. Two log decrease in serum HBV DNA was observed in 9 (31.03%) patients (95% CI: 0.14, 0.48) and 1 log decrease in 9 (31.03%) patients. Overall, 18 (62.02%) patients showed decrease in serum HBV DNA level after 16 weeks of therapy. There were 6 (20.68%) patients in which no log change in HBV DNA level was seen and in 5 (17.24%) patients, serum HBV DNA level was found elevated after therapy from baseline [ Table 4 ].
Liver cirrhosis and hepatocellular carcinoma are squealae of persistent and uncontrolled replication of HBV in the liver. [19, 20] Since serum HBV DNA level is the direct reflection of intrahepatic viral replication, IFN-α-therapy have prevented hepatic complications by arresting viral replication.
ALT level assessment was done at baseline and during therapy at week 1, week 2, week 8, week 12, and week 16. Mean ALT level started decreasing after 4 weeks of therapy but remained out of range until 16 weeks of therapy (Graph 1).
Safety results
In the study of 37 patients, a total of 18 (48.64%) subjects in the study experienced adverse events. Out of which, 10 (27.02%) subjects had at least one adverse event related to the study drug. Three subjects were discontinued due to adverse events. For the known IFN-related adverse events, 7 (18.91%) subjects had pyrexia, 2 (5.40%) subjects had myalgia, and 2 (5.40%) subjects had headache. There were 4 (10.81%) subjects with at least one adverse event, of which 2 patients were discontinued from study due to event. The reason for seriousness was hospitalization [ Table 5 ].
DISCUSSION
Chronic hepatitis B has transmission capacity, leads to high morbidity and mortality in the community. The intention of treatment of chronic hepatitis B is to achieve sustained suppression of HBV replication and remission of liver disease through ALT normalization, decrease in serum HBV DNA level, and loss of HBeAg. IFNs have antiviral, anti-proliferative, and immunomodulatory effects and effective in suppressing HBV replication and in inducing remission of liver disease. [21] [22] [23] [24] [25] [26] [27] Many clinical studies have shown that IFN-α is effective to reduce the level of serological and virological markers in chronic hepatitis B patients. [21] [22] [23] [24] [25] [26] This study was prospective, open-label, and conducted on Indian population. Thirty-seven patients were enrolled in the study, of which 29 patients completed the study. Analysis has been done on 29 patients as per protocol.
HBeAg is the most significant prognostic serological marker that coincides with high level of virus replication and reflects the presence of circulating intact virons and HBV DNA. The rate of elimination of HBeAg, HBsAg, and HBV DNA were markedly higher among the IFN-α -treated patients than untreated patient. IFN-induced HBeAg seroconversion resulted in 34.48% patients indicated that IFN-α therapy led in clearance of HBeAg and arrested the virus replication effectively and thus prevented the long-term severe complications. HBeAg seroconversion results are corresponding to other published studies [ Table 6 ].
HBV DNA level assessment done at 16 weeks was an early time point to see the response on serum HBV DNA level, but our results indicate that IFN-α therapy has effectively cleared the HBV DNA after therapy. At least 2 log decreases was observed in 9 (31.03%) patients and at least 1 log decrease in 9 (31.03%) patients. Overall decline or response to IFN therapy on HBV DNA level was observed in 62% patients after 16 weeks of therapy. IFN-α therapy has prevented hepatic complications by arresting viral replication as serum HBV DNA level is the direct reflection of intrahepatic viral replication. India spends only 5% annual gross domestic product (GDP) on health care. [28] Of this, most of the expenditure (about 80%) is private out-of-pocket. High out-of-pocket costs make health services inaccessible to a significant proportion of Indian households. Among those who decided not to seek medical care for an ailment, nearly 20% of urban and 28% rural households cited financial constraints as the limiting factor. [29] On considering the World Bank definition of poverty, according to estimates from the National Commission for Enterprises in the Unorganized Sector (NCEUS), 77% of Indians, i.e., about 836 million people, live on less than half a dollar a day. [30] In India, nearly 3.1 million additional households slip to levels below the poverty line ($1 per day) per annum as a result of hospitalization expenditure. [31] The total cost of the indigenous conventional IFN for duration of 16 weeks comes to approximately ₹ 92,000 to 95,000, whereas the cost of conventional IFN, marketed through multinational companies, is approximately ₹ 1,24,000 to 1,28,000. The per capita income at current prices during 2012-13 is estimated to be ₹ 68,747. Thus, patients can save approximately ₹ 30,000 to 33,000 on conventional IFN therapy. Even the Indian Supreme Court gave landmark judgment for promoting the generic drugs recently in the beginning of 2013.
Pegalyted-IFN has the advantages of more convenient administration, better pharmacokinetics, and more sustained viral suppression though clinical trials suggest that the efficacy of pegalyted-IFN is similar to or slightly better than standard IFN.
Our study has some limitations. First, the standard indigenous IFN has not been compared with any other IFN available in the market head to head. Second, the placebo arm was not there. Third, neither the study was blinded, nor the patients were randomized.
CONCLUSION
IFN-α treatment resulted in loss of HBeAg, HBsAg, and decreases serum HBV-DNA levels in chronic hepatitis B patients and thus prevented morbidity and mortality associated with disease. Most of adverse events were mild to moderate in intensity. So, IFN-α therapy is well tolerated, safe, and efficacious to treat HBeAg-positive chronic hepatitis B patients without decompensated liver disease.
